A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment. Pediatr Dermatol 2018 May;35(3):e165-e169
Date
03/24/2018Pubmed ID
29570823DOI
10.1111/pde.13473Scopus ID
2-s2.0-85044263206 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Sclerodermatous graft-versus-host disease is a subtype of cutaneous chronic graft-versus-host disease that is characterized by sclerosis of the skin and subcutaneous tissue, resulting in debilitating contractures, among other life-threatening complications. Children with sclerodermatous graft-versus-host disease are at high risk of developing nonmelanoma skin cancer because of several risk factors, including young age at transplantation, prolonged immunosuppression, and exposure to photosensitizing antimicrobial prophylaxis such as voriconazole. The immunosuppression required to treat sclerodermatous graft-versus-host disease makes effectively treating nonmelanoma skin cancer and sclerodermatous graft-versus-host disease in the same patient challenging. We describe a challenging case of a 6-year-old boy with a history of sclerodermatous graft-versus-host disease and voriconazole exposure presenting with squamous cell carcinoma in situ on the left temple and actinic keratoses on the scalp treated with topical chemotherapy agents.
Author List
Li AW, Lalor LE, Bellodi Schmidt F, Luu MAuthor
Leah Lalor MD Associate Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, TopicalAntifungal Agents
Bone Marrow Transplantation
Carcinoma, Squamous Cell
Dermatitis, Phototoxic
Fluorouracil
Graft vs Host Disease
Humans
Immunosuppressive Agents
Keratosis, Actinic
Male
Skin
Skin Neoplasms
Voriconazole
